Le Lézard
Classified in: Science and technology, Business
Subject: CON

Bambuser Enters Pilot Agreement with Iconic British Luxury Fashion Label for Live Video Shopping Throughout Q4 2020


STOCKHOLM, Oct. 20, 2020 /PRNewswire/ -- Bambuser AB has signed a pilot agreement to power Live Video Shopping for an iconic British luxury fashion label. The agreement gives the customer the right to use Live Video Shopping at a fixed cost of 35,000 GBP (approx 0.4 MSEK) during the 3-month period beginning October 2020. 

This is information that Bambuser AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on October 20, 2020.

Contact information

Maryam Ghahremani, CEO | +46 8 400 160 02 | ir@bambuser.com or visit bambuser.com/ir  

Certified Adviser

Erik Penser Bank AB | +46 8 463 83 00 | certifiedadviser@penser.se

Bambuser is a software company specializing in interactive live video streaming. The Company's primary product, Live Video Shopping, is a cloud-based software solution that is used by customers such as global e-commerce and retail businesses to host live shopping experiences on websites, mobile apps and social media. Bambuser was founded in 2007 and has its headquarters in Stockholm.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bambuser/r/bambuser-enters-pilot-agreement-with-iconic-british-luxury-fashion-label-for-live-video-shopping-thr,c3216652

The following files are available for download:

https://mb.cision.com/Main/15749/3216652/1321198.pdf

Release

SOURCE Bambuser


These press releases may also interest you

at 18:05
GlycoMimetics' product candidate uproleselan ? when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) ? was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor...

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple...

at 15:30
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to evaluate the...

at 15:05
bluebird bio, Inc. today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobintm for ?-thalassemia) in patients with transfusion-dependent...



News published on 20 october 2020 at 04:38 and distributed by: